- Home
- NTHI vs ASMB Comparison
NTHI vs ASMB Comparison
Compare NTHI & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- ASMB
- Stock Information
- Founded
- NTHI 2008
- ASMB 2005
- Country
- NTHI United States
- ASMB United States
- Employees
- NTHI N/A
- ASMB N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- NTHI Health Care
- ASMB Health Care
- Exchange
- NTHI Nasdaq
- ASMB Nasdaq
- Market Cap
- NTHI 195.5M
- ASMB 225.9M
- IPO Year
- NTHI N/A
- ASMB 2010
- Fundamental
- Price
- NTHI $6.40
- ASMB $37.04
- Analyst Decision
- NTHI
- ASMB Strong Buy
- Analyst Count
- NTHI 0
- ASMB 6
- Target Price
- NTHI N/A
- ASMB $43.40
- AVG Volume (30 Days)
- NTHI 62.7K
- ASMB 131.9K
- Earning Date
- NTHI 11-14-2025
- ASMB 11-10-2025
- Dividend Yield
- NTHI N/A
- ASMB N/A
- EPS Growth
- NTHI N/A
- ASMB N/A
- EPS
- NTHI N/A
- ASMB N/A
- Revenue
- NTHI $59,990.00
- ASMB $37,191,000.00
- Revenue This Year
- NTHI N/A
- ASMB $14.29
- Revenue Next Year
- NTHI N/A
- ASMB N/A
- P/E Ratio
- NTHI N/A
- ASMB N/A
- Revenue Growth
- NTHI N/A
- ASMB 31.30
- 52 Week Low
- NTHI $3.20
- ASMB $7.75
- 52 Week High
- NTHI $25.00
- ASMB $39.71
- Technical
- Relative Strength Index (RSI)
- NTHI 31.38
- ASMB 69.38
- Support Level
- NTHI $8.93
- ASMB $35.00
- Resistance Level
- NTHI $9.57
- ASMB $37.71
- Average True Range (ATR)
- NTHI 1.15
- ASMB 2.01
- MACD
- NTHI -0.46
- ASMB 0.31
- Stochastic Oscillator
- NTHI 0.00
- ASMB 70.94
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.